IQVIA Holdings Inc

IQVIA Holdings Inc(IQV)股票分析

$261.750

-0.628 (-0.24%)收盤時

Loading chart…
High
262.820
Open
260.550
VWAP
260.88
Vol
1.84M
Mkt Cap
38.76B
Low
258.080
Amount
480.59M
EV/EBITDA, TTM
16.02

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.

ir.iqvia.com

AI analysis of IQVIA Holdings Inc (IQV)

buy

IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.

Analyst Ratings (17)

-1.31% downside
Buy
9 Buy
8 Hold
0 Sell
Current: 261.75
最低
215.00
平均
258.31
最高
290.00

TD Cowen

2026-07-29

目標價

$288

Buy

BofA

2026-07-29

目標價

$280

Buy

RBC Capital

2026-07-29

目標價

$247

Outperform

BMO Capital

2026-07-29

目標價

$270

Outperform

JPMorgan

2026-07-29

目標價

$285

Overweight

估值指標

The current forward P/E ratio for IQVIA Holdings Inc (IQV) is 20.28, compared to its 5-year average forward P/E of 19.19.

Forward P/E

Fair
5Y Average P/E
19.19
Current P/E
20.28
高估
22.73
低估
15.65

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.85
Current EV/EBITDA
16.02
高估
16.09
低估
11.61

Forward P/S

Fair
5Y Average P/S
2.45
Current P/S
2.34
高估
2.95
低估
1.95

Alphio AI Price Scenarios for IQV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IQV

$150.52

情境價格

B

Base

Base · 50%IQV

$139.87

情境價格

B

Bear

Bear · 25%IQV

$124.38

情境價格

Whales holding IQV

L

Lakewood Capital Management, LP

+ HoldingIQV

+12.37%

3M Return

A

Artisan Partners Limited Partnership

+ HoldingIQV

+8.81%

3M Return

G

Greenhaven Associates Inc

+ HoldingIQV

+5.94%

3M Return

L

Longview Partners (Guernsey) Limited

+ HoldingIQV

+5.80%

3M Return

N

Nichols & Pratt Advisers LLP

+ HoldingIQV

+5.09%

3M Return

T

Thompson, Siegel & Walmsley LLC

+ HoldingIQVGOOGL

+3.94%

3M Return

事件時間軸

2026-08-04 (ET)

16:30:00

IQVIA and Medera Collaborate to Accelerate Cardiac Gene Therapy Development

2026-07-28 (ET)

12:00:00

Dow Jones Up 619 Points as Investors Eye Fed Policy Meeting

10:00:00

Notable Gainers This Morning Include IQVIA and Others

07:30:00

IQVIA Reports Q2 Revenue of $4.368B, Exceeding Expectations

07:30:00

Sees FY26 Revenue at $17.275B-$17.475B

資訊

IQV FAQ — answered by Alphio AI

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始